We are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and neuropsychiatric conditions. We anticipate that our orexin agonists may have utility in treating impaired attention, cognitive deficits, fatigue and other symptoms. We also have an early-stage immuno-oncology program focused on our LockBody^® technology platform.

Centessa’s team is made up of pioneers in their fields working to advance our core programs. Read more on the inspiring stories of the continuing journeys from vision to transformational medicines below.